Cancer Drug Development Shows That Government and Private Sector can Work Together
PALM BEACH, Florida, Feb. 5, 2019 /PRNewswire/ -- Considering that yesterday, February 4, was World
Cancer Day, it is encouraging that the private sector and the U.S. government are mutually trying to solve a serious problem and are in fact, working closely and in harmony with each other to
reach that goal, to cure cancer in all its forms. The American Society of Clinical Oncology (ASCO), the pre-emanate professional organization representing physicians of all oncology
sub-specialties who care for people with cancer, in its 2019 Annual Report on Progress Against Cancer, calls for this partnership to continue. The report says: "Now is the time to invest in
the next generation of cancer cures" and "To find the next frontier in cancer vaccines, we need our nation's support for cancer research." Says Judith S. Kaur, MD, Mayo Clinic Cancer
Center and Pioneer in cancer prevention & education. Active biotech and pharma companies in the markets this week include Moleculin Biotech, Inc. (NASDAQ:MBRX), Evolus,
Inc. (NASDAQ:EOLS), Agenus Inc. (NASDAQ:AGEN), QIAGEN N.V. (NYSE:QGEN), Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)
This FDA and private sector collaboration has been quite effective: "The number of new FDA approvals in oncology continues at a rapid pace. From November 2017 through October 2018, the FDA approved 11 new cancer therapies and 39 new uses of cancer therapies. In the same time frame in the previous year, there were 18 new cancer therapies and 13 new uses approved. The FDA, the hand of government that works the most closely with the private sector in this arena, prides itself on what this partnership has wrought: "The program has successfully enabled the development and marketing of over 600 drugs and biologic products for rare diseases since 1983. In contrast, fewer than 10 such products supported by industry came to market between 1973 and 1983. The Orphan Grants Program has been used to bring more than 60 products to marketing approval."
Moleculin Biotech, Inc. (NASDAQ:MBRX) BREAKING NEWS: Moleculin Biotech, a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Status for its drug candidate WP1066 for the treatment of glioblastoma, the most aggressive form of brain tumor.